JP2001503250A - 束縛ペプチドモチーフを用いたターゲッティングアデノウイルス - Google Patents
束縛ペプチドモチーフを用いたターゲッティングアデノウイルスInfo
- Publication number
- JP2001503250A JP2001503250A JP51096198A JP51096198A JP2001503250A JP 2001503250 A JP2001503250 A JP 2001503250A JP 51096198 A JP51096198 A JP 51096198A JP 51096198 A JP51096198 A JP 51096198A JP 2001503250 A JP2001503250 A JP 2001503250A
- Authority
- JP
- Japan
- Prior art keywords
- vector
- seq
- fiber protein
- protein
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 85
- 241000701161 unidentified adenovirus Species 0.000 title claims description 154
- 230000008685 targeting Effects 0.000 title abstract description 48
- 239000013598 vector Substances 0.000 claims abstract description 246
- 210000004027 cell Anatomy 0.000 claims abstract description 209
- 101710145505 Fiber protein Proteins 0.000 claims abstract description 119
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims abstract description 101
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 58
- 239000003446 ligand Substances 0.000 claims abstract description 14
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 11
- 101710094648 Coat protein Proteins 0.000 claims abstract description 11
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims abstract description 11
- 101710125418 Major capsid protein Proteins 0.000 claims abstract description 11
- 101710141454 Nucleoprotein Proteins 0.000 claims abstract description 11
- 101710083689 Probable capsid protein Proteins 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 159
- 102000004169 proteins and genes Human genes 0.000 claims description 99
- 235000018102 proteins Nutrition 0.000 claims description 97
- 230000027455 binding Effects 0.000 claims description 74
- 235000001014 amino acid Nutrition 0.000 claims description 50
- 150000001413 amino acids Chemical class 0.000 claims description 41
- 238000012546 transfer Methods 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 27
- 230000015861 cell surface binding Effects 0.000 claims description 17
- 235000018417 cysteine Nutrition 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 230000003993 interaction Effects 0.000 claims description 10
- 239000013603 viral vector Substances 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- MWOGMBZGFFZBMK-LJZWMIMPSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWOGMBZGFFZBMK-LJZWMIMPSA-N 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 108010052768 tyrosyl-isoleucyl-glycyl-seryl-arginine Proteins 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 150000001945 cysteines Chemical class 0.000 claims description 6
- 244000309711 non-enveloped viruses Species 0.000 claims description 6
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract description 3
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- 239000000835 fiber Substances 0.000 description 108
- 241000700605 Viruses Species 0.000 description 85
- 239000013612 plasmid Substances 0.000 description 49
- 102000005962 receptors Human genes 0.000 description 47
- 108020003175 receptors Proteins 0.000 description 47
- 102000053602 DNA Human genes 0.000 description 36
- 108091034117 Oligonucleotide Proteins 0.000 description 36
- 238000003780 insertion Methods 0.000 description 27
- 230000037431 insertion Effects 0.000 description 26
- 239000002245 particle Substances 0.000 description 26
- 230000001404 mediated effect Effects 0.000 description 23
- 238000001476 gene delivery Methods 0.000 description 17
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 15
- 239000000074 antisense oligonucleotide Substances 0.000 description 15
- 238000012230 antisense oligonucleotides Methods 0.000 description 15
- 238000001415 gene therapy Methods 0.000 description 14
- 102000006495 integrins Human genes 0.000 description 14
- 108010044426 integrins Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 108010005774 beta-Galactosidase Proteins 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 102000005936 beta-Galactosidase Human genes 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 238000010367 cloning Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 229920002477 rna polymer Polymers 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 238000010361 transduction Methods 0.000 description 8
- 230000026683 transduction Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 241000701447 unidentified baculovirus Species 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 210000000234 capsid Anatomy 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000004885 white matter Anatomy 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 102000007547 Laminin Human genes 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 108010006195 arginyl-glycyl-aspartyl-cysteine Proteins 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 238000002741 site-directed mutagenesis Methods 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000005829 trimerization reaction Methods 0.000 description 5
- AEGSIYIIMVBZQU-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxy-2-sulfanylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O AEGSIYIIMVBZQU-CIUDSAMLSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 241000271566 Aves Species 0.000 description 4
- 102000015689 E-Selectin Human genes 0.000 description 4
- 108010024212 E-Selectin Proteins 0.000 description 4
- 101150066038 E4 gene Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 108010085895 Laminin Proteins 0.000 description 4
- 102100021869 Tyrosine aminotransferase Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 241000220479 Acacia Species 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 241000450599 DNA viruses Species 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 241000519695 Ilex integra Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 102000019997 adhesion receptor Human genes 0.000 description 3
- 108010013985 adhesion receptor Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012411 cloning technique Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000007505 plaque formation Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- FMWHSNJMHUNLAG-FXQIFTODSA-N Asp-Cys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FMWHSNJMHUNLAG-FXQIFTODSA-N 0.000 description 2
- WEDGJJRCJNHYSF-SRVKXCTJSA-N Asp-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N WEDGJJRCJNHYSF-SRVKXCTJSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000713840 Avian erythroblastosis virus Species 0.000 description 2
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- CEZSLNCYQUFOSL-BQBZGAKWSA-N Cys-Arg-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O CEZSLNCYQUFOSL-BQBZGAKWSA-N 0.000 description 2
- OLIYIKRCOZBFCW-ZLUOBGJFSA-N Cys-Asp-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)C(=O)O OLIYIKRCOZBFCW-ZLUOBGJFSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000700586 Herpesviridae Species 0.000 description 2
- 101710094396 Hexon protein Proteins 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010000851 Laminin Receptors Proteins 0.000 description 2
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 2
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 2
- 241000701244 Mastadenovirus Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000701945 Parvoviridae Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 2
- 241000712907 Retroviridae Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000713824 Rous-associated virus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- BKOKTRCZXRIQPX-ZLUOBGJFSA-N Ser-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N BKOKTRCZXRIQPX-ZLUOBGJFSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000713896 Spleen necrosis virus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 108010046775 glutamyl-isoleucyl-leucyl-aspartyl-valine Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- -1 that is Chemical compound 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FLNMCNFAJCMMHI-YGHIGYJTSA-N (4s)-4-amino-5-[[(2s,3s)-1-[[(2s)-1-[[(2s)-3-carboxy-1-[[(2s)-1-[(2s)-2-[[(2s)-1-[[(1s,2r)-1-carboxy-2-hydroxypropyl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan- Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FLNMCNFAJCMMHI-YGHIGYJTSA-N 0.000 description 1
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical group FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- WBSCNDJQPKSPII-UHFFFAOYSA-N 6-amino-2-[[6-amino-2-(2,6-diaminohexanoylamino)hexanoyl]amino]hexanoic acid Chemical compound NCCCCC(N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(O)=O WBSCNDJQPKSPII-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 108010056962 Adenovirus E4 Proteins Proteins 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- ZODMADSIQZZBSQ-FXQIFTODSA-N Ala-Gln-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZODMADSIQZZBSQ-FXQIFTODSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 1
- BTJVOUQWFXABOI-IHRRRGAJSA-N Arg-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N BTJVOUQWFXABOI-IHRRRGAJSA-N 0.000 description 1
- QPDUWAUSSWGJSB-NGZCFLSTSA-N Asp-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N QPDUWAUSSWGJSB-NGZCFLSTSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000701021 Betaherpesvirinae Species 0.000 description 1
- 241000713686 Bovine lentivirus group Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- ZHCCYSDALWJITB-SRVKXCTJSA-N Cys-Phe-Cys Chemical compound N[C@@H](CS)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CS)C(O)=O ZHCCYSDALWJITB-SRVKXCTJSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 108010020195 FLAG peptide Proteins 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101100015391 Mus musculus Ralgds gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000724832 Non-A, non-B hepatitis virus Species 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FNGOXVQBBCMFKV-CIUDSAMLSA-N Pro-Ser-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O FNGOXVQBBCMFKV-CIUDSAMLSA-N 0.000 description 1
- 102100026827 Protein associated with UVRAG as autophagy enhancer Human genes 0.000 description 1
- 101710102978 Protein associated with UVRAG as autophagy enhancer Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 1
- IXCHOHLPHNGFTJ-YUMQZZPRSA-N Ser-Gly-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CO)N IXCHOHLPHNGFTJ-YUMQZZPRSA-N 0.000 description 1
- QGAHMVHBORDHDC-YUMQZZPRSA-N Ser-His-Gly Chemical compound OC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CN=CN1 QGAHMVHBORDHDC-YUMQZZPRSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GGXUDPQWAWRINY-XEGUGMAKSA-N Tyr-Ile-Gly Chemical compound OC(=O)CNC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GGXUDPQWAWRINY-XEGUGMAKSA-N 0.000 description 1
- HSBZWINKRYZCSQ-KKUMJFAQSA-N Tyr-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O HSBZWINKRYZCSQ-KKUMJFAQSA-N 0.000 description 1
- 108020004417 Untranslated RNA Proteins 0.000 description 1
- 102000039634 Untranslated RNA Human genes 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108010084938 adenovirus receptor Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 108010064033 elastin-binding proteins Proteins 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001955 intestinal smooth muscle cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011246 intracellular protein detection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009443 proangiogenesis Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10345—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- C12N2810/405—Vectors comprising RGD peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.束縛非天然アミノ酸配列を含むキメラアデノウイルスファイバー蛋白質。 2.当該キメラアデノウイルスファイバー蛋白質が、当該アデノウイルスファイ バー蛋白質を含むベクターの細胞への侵入を、当該キメラアデノウイルス蛋白質 ではなく野生型のアデノウイルスファイバー蛋白質を含んでいること以外は等し いベクターよりも、より効率的に容易にするものである、請求の範囲1に記載の キメラアデノウイルスファイバー蛋白質。 3.当該キメラアデノウイルスファイバー蛋白質が、野生型ファイバー蛋白質は 結合しない、細胞表面上に存在する結合部位に結合するものである、請求の範囲 1または2に記載のキメラアデノウイルスファイバー蛋白質。 4.当該非天然アミノ酸配列が抗体に対するエピトープまたは細胞表面結合部位 に対するリガンドを含むものである、請求の範囲1〜3のいずれかに記載のキメ ラアデノウイルスファイバー蛋白質。 5.当該非天然アミノ酸配列が約3ないし約200のアミノ酸を含むものである 、請求の範囲1〜4のいずれかに記載のキメラアデノウイルスファイバー蛋白質 。 6.当該非天然アミノ酸配列が約3ないし約30のアミノ酸を含むものである、 請求の範囲1〜4のいずれかに記載のキメラアデノウイルスファイバー蛋白質。 7.当該非天然アミノ酸配列が、配列番号1、配列番号2、配列番号3、配列番 号4、配列番号5、配列番号17、配列番号19、配列番号23、配列番号31 、配列番号35、配列番号39、配列番号43、配列番号49、配列番号53、 配列番号56、 配列番号59および配列番号63、配列番号66、配列番号67、配列番号68 、配列番号79、それらの保存的アミノ酸置換、およびそれらのCあるいはN末 端欠失(ここで当該欠失は1、2または3残基を除去するものである)からなる群 より選択される配列を含むものである、請求の範囲1〜4のいずれかに記載のキ メラアデノウイルスファイバー蛋白質。 8.当該ファイバー蛋白質がノブを有し、該ノブが1またはそれ以上のループを 有し、且つ当該非天然アミノ酸配列が当該ノブのAB、CD、DG、GH、IJ およびHIループからなる群より選択されるループの天然アミノ酸配列中に、あ るいはそれに代えて挿入されるものである請求の範囲1〜7のいずれかに記載の キメラアデノウイルスファイバー蛋白質。 9.当該非天然アミノ酸配列が、配列番号3、配列番号4および配列番号5、そ れらの保存的アミノ酸置換およびそれらのCあるいはN末端欠失(当該欠失は1 、2または3残基を除去するものである)からなる群より選択される配列を含む ものである請求の範囲1〜8のいずれかに記載のキメラアデノウイルスファイバ ー蛋白質。 10.当該非天然アミノ酸配列が、RGD配列ならびに1またはそれ以上のシス テイン対を保有することによって束縛されているものである、請求の範囲1〜9 のいずれかに記載のキメラアデノウイルスファイバー蛋白質。 11.当該非天然アミノ酸配列が、キメラアデノウイルスファイバー蛋白質のC 末端の蛋白質配列中に、あるいはそれに代えて挿入されるものである請求の範囲 1〜10のいずれかに記載のキメラアデノウイルスファイバー蛋白質。 12.請求の範囲1〜11のいずれかに記載のキメラアデノウイルスファイバー 蛋白質をコードする、単離または精製した核酸。 13.請求の範囲12に記載の該単離または精製した核酸を含む導入ベクター。 14.当該導入ベクターがp193(F5*)、p193 F52K(RKKK2 )、p193 F5F2K、p193(F5)pGS(RGD)、p193(F 5)pLDV、p193(F5)pYIGSR、p193(F5*)RGD、お よびp193 F552K(FLAG)からなる群より選択されるものである、 請求の範囲13に記載の導入ベクター。 15.請求の範囲1〜11のいずれかに記載のキメラアデノウイルスファイバー 蛋白質を含むベクター。 16.当該ベクターが非エンベロープウイルス類からなる群より選択されるウイ ルスベクターである、請求の範囲15に記載のベクター。 17.当該ベクターがアデノウイルスベクターである請求の範囲15または16 に記載のベクター。 18.当該ベクターがAdZ.FLAG、AdZ.RKKK2、AdZ.pRG D、AdZ.RGD、AdZ.pLDVおよびAdZ.YIGSRからなる群よ り選択されるものである、請求の範囲17に記載のベクター。 19.当該ベクターがさらに、パッセンジャー遺伝子(ウイルスゲノムに挿入さ れているか、または蛋白質/DNA相互作用によって当該アデノウイルスのコー ト蛋白質に接着している)を含んでいる請求の範囲15〜18のいずれかに記載 のベクター。 20.請求の範囲1〜11のいずれかに記載のキメラアデノウイルスファイバー 蛋白質で、ベクターのファイバー蛋白質を置換することを含む、当該ファイバー 蛋白質を含むベクターの細胞内への侵入効率を増加させる方法。 21.請求の範囲13〜19のいずれかに記載のベクターに細胞を接触させるこ とを含む、当該細胞を遺伝的に修飾する方法。 22.請求の範囲13〜19のいずれかに記載のベクターを含む宿主細胞。 23.(a)野生型アデノウイルスファイバー蛋白質を取得し、 (b)キメラアデノウイルスファイバー蛋白質が結果としてできるように、 当該野生型アデノウイルスファイバー蛋白質の当該ノブのループ内の蛋白質配列 中に、あるいはそれに代えて非天然アミノ酸配列を挿入する、ことを含む細胞表 面結合部位へのペプチドの親和性を増大させる方法。 24.(a)野生型アデノウイルスファイバー蛋白質を取得し、 (b)1またはそれ以上のシステイン対によって側面を固めて、該システイ ン間の相互作用によってループを形成することが可能なように、当該野生型アデ ノウイルスファイバー蛋白質の蛋白質配列内に、あるいはそれに代えてRGD配 列を挿入する、ことを含む細胞表面結合部位へのRGD配列の親和性を増大させ る方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/701,124 US5846782A (en) | 1995-11-28 | 1996-08-21 | Targeting adenovirus with use of constrained peptide motifs |
US08/701,124 | 1996-08-21 | ||
PCT/US1997/014719 WO1998007865A1 (en) | 1996-08-21 | 1997-08-21 | Targeting adenovirus with use of constrained peptide motifs |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001503250A true JP2001503250A (ja) | 2001-03-13 |
Family
ID=24816168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51096198A Ceased JP2001503250A (ja) | 1996-08-21 | 1997-08-21 | 束縛ペプチドモチーフを用いたターゲッティングアデノウイルス |
Country Status (9)
Country | Link |
---|---|
US (4) | US5846782A (ja) |
EP (1) | EP0920514B1 (ja) |
JP (1) | JP2001503250A (ja) |
AT (1) | ATE382695T1 (ja) |
AU (1) | AU732770B2 (ja) |
CA (1) | CA2263140A1 (ja) |
DE (1) | DE69738432T2 (ja) |
HU (1) | HUP0001120A2 (ja) |
WO (1) | WO1998007865A1 (ja) |
Families Citing this family (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5820868A (en) | 1993-12-09 | 1998-10-13 | Veterinary Infectious Disease Organization | Recombinant protein production in bovine adenovirus expression vector system |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
EP0833934B2 (en) * | 1995-06-15 | 2012-08-15 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US6420629B1 (en) * | 1996-09-09 | 2002-07-16 | B.C. Research Inc. | Process of increasing plant growth and yield and modifying cellulose production in plants |
FR2758822B1 (fr) * | 1997-01-30 | 1999-07-02 | Centre Nat Rech Scient | Utilisation d'un polypeptide a titre de recepteur cellulaire des adenovirus |
US6432699B1 (en) * | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
FR2761689B1 (fr) * | 1997-04-02 | 1999-06-25 | Transgene Sa | Fibre adenovirale modifiee et adenovirus cibles |
HUP0002070A2 (hu) * | 1997-05-28 | 2000-10-28 | Genvec, Inc. | Alternatív módon célba juttatott adenovírus |
CA2294649C (en) | 1997-06-23 | 2007-09-25 | University Of Saskatchewan | Bovine adenovirus type 3 genome |
WO1999039734A1 (en) * | 1998-02-06 | 1999-08-12 | The Uab Research Foundation | Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob |
US20050095231A1 (en) * | 1998-02-17 | 2005-05-05 | Curiel David T. | Modified adenovirus containing a fiber replacement protein |
US6815200B1 (en) | 1998-02-17 | 2004-11-09 | The Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
CA2321135A1 (en) * | 1998-02-17 | 1999-08-19 | Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
WO1999055365A1 (en) | 1998-04-30 | 1999-11-04 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
US20030017138A1 (en) * | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US20040043489A1 (en) * | 1998-07-08 | 2004-03-04 | Menzo Havenga | Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use |
HUP0200073A3 (en) * | 1998-08-27 | 2003-12-29 | Aventis Pharma Sa | Targeted adenovirus vectors for delivery of heterologous genes |
US6284742B1 (en) * | 1998-09-29 | 2001-09-04 | Uab Research Foundation | Immunomodulation by genetic modification of dendritic cells and B cells |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US7157266B2 (en) * | 1999-01-25 | 2007-01-02 | Brookhaven Science Associates Llc | Structure of adenovirus bound to cellular receptor car |
US6395875B1 (en) * | 1999-01-25 | 2002-05-28 | Brookhaven Science Associates Llc | Recombinant soluble adenovirus receptor |
JP2000279178A (ja) * | 1999-02-24 | 2000-10-10 | Japan Found Cancer Res | ウイルスベクター |
US6869936B1 (en) * | 1999-03-04 | 2005-03-22 | Crucell Holland B.V. | Means and methods for fibroblast-like or macrophage-like cell transduction |
US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
CA2384338A1 (en) * | 1999-05-12 | 2000-11-16 | The Uab Research Foundation | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
AU777120B2 (en) * | 1999-06-11 | 2004-09-30 | Medigene, Inc. | Use of viral vectors and charged molecules for gene therapy |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6740511B1 (en) * | 1999-08-27 | 2004-05-25 | Transgene S.A. | Modified adenoviral fibre and uses thereof |
ES2183752T3 (es) * | 1999-09-17 | 2005-07-16 | Tgt Laboratories, S.A. De C.V. | Vectores adenovirales recombinantes y su utilizacion en el tratamiento de la cirrosis de higado. |
DE60031994T2 (de) * | 1999-09-24 | 2007-09-20 | The Uab Research Foundation, Birmingham | Kapsidmodifiziertes rekombinantes Adenovirus und Verfahren zu dessen Anwendung |
US6955808B2 (en) * | 1999-09-24 | 2005-10-18 | Uab Research Foundation | Capsid-modified recombinant adenovirus and methods of use |
AU1087701A (en) | 1999-10-15 | 2001-04-30 | Canji, Inc. | Targeted vectors |
WO2001038361A1 (fr) * | 1999-11-25 | 2001-05-31 | Transgene S.A. | Fibre adenovirable modifiee et utilisations |
AU2001250683B2 (en) * | 2000-04-12 | 2006-06-29 | Ge Healthcare As | Peptide-based compounds |
US7332337B2 (en) * | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
EP1157999A1 (en) * | 2000-05-24 | 2001-11-28 | Introgene B.V. | Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof |
EP1285081A2 (en) * | 2000-05-30 | 2003-02-26 | ICH Productions Limited | Improved methods of transfection |
CA2410981A1 (en) * | 2000-06-02 | 2001-12-06 | Novartis Ag | Adenovirus particles with mutagenized fiber proteins |
US6762031B2 (en) | 2000-06-16 | 2004-07-13 | University Of Medicine And Dentistry Of New Jersey | Targeting viral vectors to specific cells |
US6524572B1 (en) * | 2000-06-26 | 2003-02-25 | Rainbow Therapeutic Company | Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy |
US20020164333A1 (en) * | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
GB0017720D0 (en) * | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
DE60116513T2 (de) * | 2000-08-10 | 2006-09-21 | Crucell Holland B.V. | Adenovirenvektoren zur transduktion der chondrozyten |
WO2002024730A2 (en) * | 2000-09-20 | 2002-03-28 | Crucell Holland B.V. | Transduction of dendritic cells using adenoviral vectors |
DE60138403D1 (de) * | 2000-09-26 | 2009-05-28 | Crucell Holland Bv | Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten |
EP1191104A1 (en) * | 2000-09-26 | 2002-03-27 | Introgene B.V. | Gene delivery vehicles and use thereof in the preparation of a medicament and/or vaccine |
NO20004795D0 (no) * | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
US6573092B1 (en) * | 2000-10-10 | 2003-06-03 | Genvec, Inc. | Method of preparing a eukaryotic viral vector |
US20030202963A1 (en) * | 2000-10-12 | 2003-10-30 | Cornell Research Foundation, Inc. | Method of treating cancer |
MXPA00011713A (es) * | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe |
AU2002250081A1 (en) * | 2001-02-14 | 2002-08-28 | Uab Research Foundation | Combined transductional and transcriptional targeting system for improved gene delivery |
US20030138405A1 (en) * | 2001-04-17 | 2003-07-24 | Juan Fueyo | Conditionally replicative adenovirus to target the Rb and Rb-related pathways |
CA2452923C (en) * | 2001-07-10 | 2012-02-07 | Amersham Health As | Peptide-based compounds for targeting integrin receptors |
US20060275262A1 (en) * | 2001-07-26 | 2006-12-07 | Mathis James M | Conditionally replicating viruses and methods for cancer virotherapy |
WO2003062400A2 (en) * | 2002-01-24 | 2003-07-31 | The Scripps Research Institute | Fiber shaft modifications for efficient targeting |
PT1497438E (pt) * | 2002-04-25 | 2010-02-04 | Crucell Holland Bv | Meios e métodos para a produção de vectores de adenovírus |
US20030206916A1 (en) * | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
CN1548537B (zh) * | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
US20040166091A1 (en) * | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
US20070212675A1 (en) * | 2003-04-15 | 2007-09-13 | Novartis Ag | Flap Endonuclease (Fen1) Regulatory Sequences And Uses Thereof |
US20070275915A1 (en) * | 2003-04-15 | 2007-11-29 | Cell Genesys, Inc. | Tmprss2 Regulatory Sequences and Uses Thereof |
WO2004101799A2 (en) | 2003-05-14 | 2004-11-25 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Broadening adenovirus tropism |
US7491508B2 (en) * | 2003-06-20 | 2009-02-17 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
US7291498B2 (en) * | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
EP1649028B1 (en) * | 2003-07-25 | 2012-08-22 | Genvec, Inc. | Adenoviral vector-based vaccines |
US7519698B2 (en) * | 2003-09-26 | 2009-04-14 | Ricoh Co., Ltd. | Method and system for extracting information from networked devices in a multi-protocol remote monitoring system |
JP2007511507A (ja) * | 2003-11-14 | 2007-05-10 | ジェンベク、インコーポレイティッド | 癌を処置するための治療レジメン |
DE602005015332D1 (de) * | 2004-02-23 | 2009-08-20 | Crucell Holland Bv | Verfahren zur Reinigung von Viren |
WO2005086922A2 (en) * | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
US7473418B2 (en) * | 2004-03-25 | 2009-01-06 | Cell Genesys, Inc. | Pan cancer oncolytic vectors and methods of use thereof |
US20070207166A1 (en) | 2004-04-12 | 2007-09-06 | Genvec, Inc. | Method of Using Adenoviral Vectors to Induce an Immune Response |
JP2008500364A (ja) | 2004-05-25 | 2008-01-10 | キメラコア, インコーポレイテッド | 自己集合性ナノ粒子薬物送達システム |
US20060062764A1 (en) * | 2004-08-25 | 2006-03-23 | Seshidar-Reddy Police | Fiber-modified adenoviral vectors for enhanced transduction of tumor cells |
EP1784493A2 (en) * | 2004-09-01 | 2007-05-16 | The Government of the United States of America as Represented by The Department of Health and Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
US20060057127A1 (en) * | 2004-09-10 | 2006-03-16 | Pocheng Liu | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
JP2008515908A (ja) | 2004-10-06 | 2008-05-15 | ユニバーシティー オブ ロチェスター | 組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療 |
CN101203530A (zh) * | 2004-10-28 | 2008-06-18 | 匹兹堡大学高等教育联邦体系 | 关于脊髓损伤疼痛的外周递送的谷氨酸脱羧酶基因治疗 |
AU2006206376B2 (en) | 2005-01-20 | 2012-03-08 | University Of Rochester | Thioredoxin interacting protein (TXNIP) as regulator of vascular function |
US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
WO2006108707A1 (en) * | 2005-04-11 | 2006-10-19 | Crucell Holland B.V. | Virus purification using ultrafiltration |
US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
WO2006132925A2 (en) * | 2005-06-01 | 2006-12-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
WO2006130806A2 (en) * | 2005-06-01 | 2006-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Assay for agonists and antagonists of ion channels and for regulators of genetic expression |
WO2007025178A2 (en) * | 2005-08-26 | 2007-03-01 | New York University | Rolyvalent multimeric compositions containing active polypeptides, pharmaceutical compositions and methods of using the same |
US8450055B2 (en) * | 2005-08-31 | 2013-05-28 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
US9651543B2 (en) | 2005-08-31 | 2017-05-16 | The United States Of America As Represented By The Secretary Of The Navy | Malaria antigen screening method |
AU2006284756B2 (en) * | 2005-08-31 | 2012-06-07 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
WO2007059461A2 (en) * | 2005-11-10 | 2007-05-24 | Genvec, Inc. | Adenoviral vector-based foot-and-mouth disease vaccine |
ES2363891T3 (es) | 2006-03-20 | 2011-08-18 | The Regents Of The University Of California | Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer. |
US8518105B2 (en) * | 2006-03-24 | 2013-08-27 | Abbott Cardiovascular System Inc. | Methods and apparatuses for coating a lesion |
JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ctla−4抗体の限局性分泌のための方法および組成物 |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
CA2648581A1 (en) | 2006-04-07 | 2008-09-12 | Chimeros, Inc. | Compositions and methods for treating b- cell malignancies |
US20100278870A1 (en) * | 2007-01-09 | 2010-11-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Adenoviral vector-based malaria vaccines |
ES2322637B1 (es) * | 2007-06-26 | 2010-03-05 | Universidad Del Pais Vasco | Microparticulas de alginato modificado con rgd como sistema de liberacion de farmacos. |
JP5548616B2 (ja) | 2007-08-08 | 2014-07-16 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Vegfr−1/nrp−1標的化ペプチド |
WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
US20090202492A1 (en) * | 2008-01-25 | 2009-08-13 | University Of South Florida | Adenovirus vaccine utilizing ikk as adjuvant |
BRPI0921651A2 (pt) * | 2008-11-03 | 2015-08-18 | Crucell Holland Bv | Método para produzir adenovírus recombinante, e partículas virais, e, biorreator |
EP2374002A1 (en) | 2008-12-23 | 2011-10-12 | GE Healthcare UK Limited | Application of 99mtc peptide-based compound as a bone marrow imaging agent |
US8772238B2 (en) | 2009-03-18 | 2014-07-08 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer |
WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
EP3329932A1 (en) | 2009-06-10 | 2018-06-06 | New York University | Immunological targeting of pathological tau proteins |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
BR112012008507B8 (pt) | 2009-10-15 | 2021-05-25 | Crucell Holland Bv | método para purificar partículas de adenovírus a partir de uma suspensão de célula |
JP5393896B2 (ja) | 2009-10-15 | 2014-01-22 | クルセル ホランド ベー ヴェー | アデノウイルス粒子の精製方法 |
US20120219583A1 (en) | 2009-10-16 | 2012-08-30 | Los Alamos National Security, Llc | Nucleic acid sequences encoding expandable hiv mosaic proteins |
WO2011057254A2 (en) | 2009-11-09 | 2011-05-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Simian adenoviral vector-based vaccines |
EP2853266B1 (en) | 2009-11-09 | 2018-01-31 | Genvec, Inc. | Method of propagating monkey adenoviral vectors |
ES2578514T3 (es) | 2010-02-15 | 2016-07-27 | Crucell Holland B.V. | Método para la producción de vectores adenovíricos |
CN103038343A (zh) | 2010-03-23 | 2013-04-10 | 英特瑞克斯顿股份有限公司 | 条件表达治疗蛋白的载体,包含所述载体的宿主细胞,及其应用 |
WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
AP3390A (en) | 2010-09-20 | 2015-08-31 | Crucell Holland Bv | Therapeutic vaccination against active tuberculosis |
WO2012041669A1 (en) | 2010-09-27 | 2012-04-05 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
WO2012083297A2 (en) | 2010-12-17 | 2012-06-21 | Genvec, Inc. | Adenoviral vectors with modified hexon regions |
WO2012088041A1 (en) | 2010-12-20 | 2012-06-28 | Genvec, Inc. | Adenoviral vector-based dengue fever vaccine |
US20130344053A1 (en) | 2010-12-28 | 2013-12-26 | University Of Rochester | Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides |
SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
ES2791760T3 (es) | 2011-09-07 | 2020-11-05 | Sinai School Medicine | Ceramidasa y diferenciación celular |
AU2012305714A1 (en) | 2011-09-09 | 2014-03-27 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
EP2780034A1 (en) | 2011-11-14 | 2014-09-24 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
EP2806883B1 (en) | 2012-01-25 | 2019-04-24 | DNAtrix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
CN104271748B9 (zh) | 2012-02-02 | 2019-05-24 | 得克萨斯州大学系统董事会 | 表达异源肿瘤相关抗原的腺病毒 |
CN104428009A (zh) | 2012-02-07 | 2015-03-18 | 全球生物疗法美国有限公司 | 核酸输送的区室化方法及其组合物和应用 |
DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
WO2013181128A1 (en) | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Modified serotype 28 adenoviral vectors |
WO2014063155A1 (en) | 2012-10-21 | 2014-04-24 | University Of Rochester | Thy1 (cd90) as a novel therapy to control adipose tissue accumulation |
CA3115891A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
WO2014176259A1 (en) | 2013-04-22 | 2014-10-30 | Icahn School Of Medicine At Mount Sinai | Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis |
PL2988780T3 (pl) | 2013-04-25 | 2019-06-28 | Janssen Vaccines & Prevention B.V. | Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV |
BR112015031509B1 (pt) | 2013-06-17 | 2023-05-09 | Janssen Vaccines & Prevention B.V. | Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende |
CA2920261C (en) | 2013-08-08 | 2018-04-03 | Global Bio Therapeutics, Inc. | Clamp device for minimally invasive procedures and uses thereof |
CN105899154B (zh) | 2013-08-08 | 2018-09-21 | 全球生物疗法有限公司 | 用于微创手术过程的注射装置和其应用 |
MX369156B (es) | 2013-09-19 | 2019-10-30 | Janssen Vaccines & Prevention Bv | Formulaciones de adenovirus mejoradas. |
WO2016037163A1 (en) | 2014-09-07 | 2016-03-10 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses |
TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
PT3215187T (pt) | 2014-11-04 | 2018-11-27 | Janssen Vaccines & Prevention Bv | Vacinas terapêuticas contra hpv16 |
EP3271729B1 (en) | 2015-03-18 | 2020-09-23 | Janssen Vaccines & Prevention B.V. | Assays for recombinant expression systems |
SI3283634T1 (sl) | 2015-04-14 | 2019-08-30 | Janssen Vaccines & Prevention B.V. | Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem |
CA2991540A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion respiratory syncytial sirus polypeptides |
CN107847580B (zh) | 2015-07-07 | 2022-08-12 | 扬森疫苗与预防公司 | 针对rsv的疫苗 |
MX2018002106A (es) | 2015-08-20 | 2018-06-15 | Janssen Vaccines & Prevention Bv | Vacunas terapeuticas contra el hpv18. |
AU2016336235B2 (en) | 2015-10-06 | 2019-10-03 | Janssen Vaccines & Prevention B.V. | Methods for preventing plastic-induced degradation of biologicals |
US11273151B2 (en) | 2015-11-04 | 2022-03-15 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
CN108699566B (zh) | 2016-02-23 | 2023-06-30 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
EP3390428B1 (en) | 2016-02-23 | 2019-09-25 | Salk Institute for Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
MX2018012095A (es) | 2016-04-05 | 2019-01-10 | Janssen Vaccines & Prevention Bv | Vacuna contra vrs. |
WO2017174568A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f proteins |
WO2017189730A1 (en) | 2016-04-26 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
JP7053491B2 (ja) | 2016-05-02 | 2022-04-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 治療用hpvワクチン組み合わせ |
US11473105B2 (en) | 2016-05-12 | 2022-10-18 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
CN109311946A (zh) | 2016-05-30 | 2019-02-05 | 扬森疫苗与预防公司 | 稳定化的融合前rsv f蛋白 |
MX2018015540A (es) | 2016-06-20 | 2019-04-11 | Janssen Vaccines & Prevention Bv | Promotor bidireccional potente y equilibrado. |
EP3484506A1 (en) | 2016-07-14 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
EP3500696A4 (en) | 2016-08-16 | 2020-04-08 | Bluebird Bio, Inc. | IL-10 RECEPTOR ALPHA HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS FOR USE |
US20190262398A1 (en) | 2016-08-23 | 2019-08-29 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
CA3035455A1 (en) | 2016-09-08 | 2018-03-15 | Bluebird Bio, Inc. | Pd-1 homing endonuclease variants, compositions, and methods of use |
CA3038968A1 (en) | 2016-09-30 | 2018-04-05 | Genvec, Inc. | Adenovectors for delivery of therapeutic genetic material into t cells |
US11530395B2 (en) | 2016-10-17 | 2022-12-20 | 2Seventy Bio, Inc. | TGFBetaR2 endonuclease variants, compositions, and methods of use |
MX2019005724A (es) | 2016-11-17 | 2019-07-08 | Bluebird Bio Inc | Conversor de se?ales de tgfbeta. |
AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
AU2018205496A1 (en) | 2017-01-07 | 2019-07-25 | Selecta Biosciences, Inc. | Patterned dosing of immunosuppressants coupled to synthetic nanocarriers |
WO2018146205A1 (en) | 2017-02-09 | 2018-08-16 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
EP3583203B1 (en) | 2017-02-15 | 2023-11-01 | 2seventy bio, Inc. | Donor repair templates multiplex genome editing |
WO2018165867A1 (zh) * | 2017-03-14 | 2018-09-20 | 浙江日升昌药业有限公司 | 肿瘤靶向多肽、制备方法及其应用 |
JP7291398B2 (ja) | 2017-03-30 | 2023-06-15 | ザ ユニバーシティー オブ クイーンズランド | キメラ分子およびその使用 |
AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
MA48797A (fr) | 2017-05-25 | 2020-04-08 | Bluebird Bio Inc | Variants de l'endonucléase cblb , compositions et procédés d'utilisation |
CA3073790A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
US11779654B2 (en) | 2017-10-04 | 2023-10-10 | 2Seventy Bio, Inc. | PCSK9 endonuclease variants, compositions, and methods of use |
AU2018347583A1 (en) | 2017-10-13 | 2020-05-21 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector IgM responses |
EA202091104A1 (ru) | 2017-10-31 | 2020-08-12 | Янссен Вэксинс Энд Превеншн Б.В. | Аденовирус и пути его применения |
EP3704138A1 (en) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention B.V. | Adenovirus and uses thereof |
AU2018359494A1 (en) | 2017-10-31 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
CN111295391B (zh) | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | 腺病毒及其用途 |
PT3743106T (pt) | 2018-01-23 | 2022-08-24 | Janssen Vaccines & Prevention Bv | Vacinas contra o vírus da influenza e suas utilizações |
CN112384204B (zh) | 2018-02-26 | 2023-03-14 | 安托瑞斯公司 | 致耐受性脂质体及其使用方法 |
CA3092353A1 (en) * | 2018-03-16 | 2019-09-19 | Research Institute At Nationwide Children's Hospital | Increasing tissue specific gene delivery by capsid modification |
DK3806903T3 (da) | 2018-06-14 | 2024-04-15 | 2Seventy Bio Inc | Cd79a kimæriske antigenreceptorer |
WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
CN113710810A (zh) | 2019-02-21 | 2021-11-26 | 安利舒免疫溶瘤技术公司 | 溶瘤腺病毒载体和使用方法 |
JP2022530439A (ja) | 2019-04-25 | 2022-06-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 組換えインフルエンザ抗原 |
AU2020265215A1 (en) | 2019-04-28 | 2021-11-18 | Selecta Biosciences, Inc. | Methods for treatment of subjects with preexisting immunity to viral transfer vectors |
BR112021022087A2 (pt) | 2019-05-15 | 2021-12-28 | Janssen Vaccines & Prevention Bv | Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus |
CA3140234A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
WO2020243261A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
US20230250135A1 (en) | 2019-09-05 | 2023-08-10 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
US20220372515A1 (en) | 2019-10-03 | 2022-11-24 | Janssen Vaccines & Prevention B.V. | Adenovirus vectors and uses thereof |
JP2022551483A (ja) | 2019-10-08 | 2022-12-09 | トラスティーズ オブ ボストン カレッジ | 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法 |
EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
CN115484978A (zh) | 2020-03-05 | 2022-12-16 | 尼奥克斯医疗有限公司 | 使用免疫细胞治疗癌症的方法和组合物 |
WO2021207636A2 (en) | 2020-04-10 | 2021-10-14 | Sola Biosciences Llc | Compositions and methods for the treatment of protein aggregation disorders |
EP4135757A1 (en) | 2020-04-13 | 2023-02-22 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
EP4143215A2 (en) | 2020-04-28 | 2023-03-08 | SOLA Biosciences LLC | Compositions and methods for the treatment of tdp-43 proteinopathies |
WO2021248038A1 (en) | 2020-06-05 | 2021-12-09 | Sola Biosciences Llc | Compositions and methods for the treatment of synucleinopathies |
CA3181983A1 (en) | 2020-06-09 | 2021-12-16 | Zhiliang Cheng | Soluble enpp1 or enpp3 proteins and uses thereof |
WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
US20230035403A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Method For Determining Responsiveness To Prostate Cancer Treatment |
WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
AU2021367952A1 (en) | 2020-10-26 | 2023-06-08 | Sola Biosciences Llc | Compositions and methods for the treatment of alzheimer's disease |
AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
CA3234720A1 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of p53-mediated cancers |
WO2023060221A2 (en) | 2021-10-08 | 2023-04-13 | Sola Biosciences Llc | Compositions and methods for the treatment of proteopathies |
WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
EP4338727A1 (en) | 2022-09-14 | 2024-03-20 | Roquette Freres | Adenovirus formulations |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
US4487829A (en) * | 1982-03-23 | 1984-12-11 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies against adenoviruses |
US4589881A (en) * | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4578079A (en) * | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4517686A (en) * | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) * | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
FR2602790B1 (fr) * | 1986-08-13 | 1990-06-01 | Transgene Sa | Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4956281A (en) * | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
US5674722A (en) * | 1987-12-11 | 1997-10-07 | Somatix Therapy Corporation | Genetic modification of endothelial cells |
US5672344A (en) * | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP2646013B2 (ja) * | 1988-09-14 | 1997-08-25 | 株式会社ジャパンエナジー | 抗ウイルス剤 |
US5204445A (en) * | 1988-10-03 | 1993-04-20 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
EP0466815A4 (en) * | 1989-04-05 | 1992-09-02 | Novacell Corpporation | Infectious targetted replication-defective virion |
US5223394A (en) * | 1989-04-10 | 1993-06-29 | Biogen, Inc. | Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence |
CA2062795A1 (en) * | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
US5240846A (en) * | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
US5332567A (en) * | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5436146A (en) * | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
ES2132072T3 (es) * | 1989-10-20 | 1999-08-16 | Dartmouth College | Anticuerpo monoclonal especifico para receptor iga. |
WO1991005871A1 (en) * | 1989-10-20 | 1991-05-02 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
WO1991018088A1 (en) * | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US5246921A (en) * | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
GB2246779B (en) * | 1990-08-03 | 1994-08-17 | Delta Biotechnology Ltd | Tumour-associated protease inhibitors targeted to tumour cells |
CA2092323A1 (en) * | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
GB9101550D0 (en) * | 1991-01-24 | 1991-03-06 | Mastico Robert A | Antigen-presenting chimaeric protein |
AU663725B2 (en) * | 1991-08-20 | 1995-10-19 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Adenovirus mediated transfer of genes to the gastrointestinal tract |
FR2681786A1 (fr) * | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
IL103059A0 (en) * | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
SE503225C2 (sv) * | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
US5661133B1 (en) * | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
JPH07507689A (ja) * | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
ATE245703T1 (de) * | 1992-09-22 | 2003-08-15 | Biofocus Discovery Ltd | Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren |
ATE404683T1 (de) * | 1992-09-25 | 2008-08-15 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
DE69333886T2 (de) * | 1992-11-18 | 2006-07-27 | Arch Development Corp., Chicago | Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel |
GB9300686D0 (en) * | 1993-01-15 | 1993-03-03 | Imp Cancer Res Tech | Compounds for targeting |
AU6133394A (en) * | 1993-02-09 | 1994-08-29 | Scripps Research Institute, The | Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton |
DE4311651A1 (de) * | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
DE69431106T2 (de) * | 1993-05-10 | 2003-05-08 | Univ Michigan Ann Arbor | Gentransfer zu den pankreatischen epithelzellen |
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
WO1995006745A1 (de) * | 1993-09-03 | 1995-03-09 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Vektor für leber-gentherapie |
US5552311A (en) * | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
US5534423A (en) * | 1993-10-08 | 1996-07-09 | Regents Of The University Of Michigan | Methods of increasing rates of infection by directing motion of vectors |
FR2712812B1 (fr) * | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
IT1271461B (it) * | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. |
US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
US6312699B1 (en) * | 1994-03-28 | 2001-11-06 | Uab Research Foundation | Ligands added to adenovirus fiber |
US7252989B1 (en) * | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
ATE200105T1 (de) * | 1994-05-13 | 2001-04-15 | Chiron Corp | Verfahren und zusammensetzungen als vehikel zur zielgerichtete einbringen von genen |
US5571531A (en) * | 1994-05-18 | 1996-11-05 | Mcmaster University | Microparticle delivery system with a functionalized silicone bonded to the matrix |
FR2721943B1 (fr) * | 1994-06-29 | 1996-08-02 | Rhone Poulenc Rorer Sa | Adenovirus comprenant un gene codant pour une superoxyde dismutase |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5962311A (en) * | 1994-09-08 | 1999-10-05 | Genvec, Inc. | Short-shafted adenoviral fiber and its use |
AU705595B2 (en) * | 1994-09-09 | 1999-05-27 | Neurocrine Biosciences, Incorporated | Interleukin-1 type 3 receptors |
FR2724846B1 (fr) * | 1994-09-27 | 1996-12-20 | Rhone Poulenc Rorer Sa | Methode de traitement des cancers par regulation de l'activite des proteines ras |
PT787200E (pt) * | 1994-10-28 | 2005-08-31 | Univ Pennsylvania | Adenovirus melhorado e metodos para a sua utilizacao |
WO1996014837A1 (en) * | 1994-11-09 | 1996-05-23 | Genetic Therapy, Inc. | Gene therapy for hypercholesterolemia |
EP0795606B1 (en) * | 1994-11-29 | 2000-08-16 | Takara Shuzo Co. Ltd. | Process for producing transformed cell |
FR2727867B1 (fr) * | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
US5770442A (en) * | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
US5622699A (en) * | 1995-09-11 | 1997-04-22 | La Jolla Cancer Research Foundation | Method of identifying molecules that home to a selected organ in vivo |
PL327038A1 (en) * | 1995-11-28 | 1998-11-09 | Genvec Inc | Vectors for and methods of transferring genes into cells |
JP2001519647A (ja) * | 1995-12-28 | 2001-10-23 | カイロン コーポレイション | 標的細胞中へのウイルスおよび粒子の取り込みおよびインターナリゼーションのためのレセプター特異的キメラウイルス表面ポリペプチド |
AU2678097A (en) * | 1996-04-16 | 1997-11-07 | Immusol Incorporated | Targeted viral vectors |
WO1998011221A2 (en) * | 1996-09-13 | 1998-03-19 | Dana-Farber Cancer Institute | Car, a novel coxsackievirus and adenovirus receptor |
CA2266342C (en) * | 1996-09-25 | 2010-06-08 | Novartis Ag | Packaging cell lines for use in facilitating the development of high-capacity adenoviral vectors |
US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
US5922315A (en) * | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
US6407200B1 (en) | 2001-06-21 | 2002-06-18 | General Electric Company | Method of preparing a poly(arylene ether), and a poly(arylene ether) prepared thereby |
-
1996
- 1996-08-21 US US08/701,124 patent/US5846782A/en not_active Expired - Lifetime
- 1996-11-27 HU HU0001120A patent/HUP0001120A2/hu unknown
-
1997
- 1997-08-21 EP EP97938497A patent/EP0920514B1/en not_active Expired - Lifetime
- 1997-08-21 AT AT97938497T patent/ATE382695T1/de not_active IP Right Cessation
- 1997-08-21 DE DE69738432T patent/DE69738432T2/de not_active Expired - Fee Related
- 1997-08-21 WO PCT/US1997/014719 patent/WO1998007865A1/en active IP Right Grant
- 1997-08-21 AU AU40804/97A patent/AU732770B2/en not_active Ceased
- 1997-08-21 CA CA002263140A patent/CA2263140A1/en not_active Abandoned
- 1997-08-21 JP JP51096198A patent/JP2001503250A/ja not_active Ceased
-
1998
- 1998-08-06 US US09/130,225 patent/US6057155A/en not_active Expired - Lifetime
-
1999
- 1999-12-06 US US09/455,061 patent/US6329190B1/en not_active Expired - Fee Related
-
2001
- 2001-10-01 US US09/969,192 patent/US6649407B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5846782A (en) | 1998-12-08 |
AU4080497A (en) | 1998-03-06 |
US6057155A (en) | 2000-05-02 |
ATE382695T1 (de) | 2008-01-15 |
HUP0001120A2 (en) | 2000-07-28 |
CA2263140A1 (en) | 1998-02-26 |
DE69738432D1 (de) | 2008-02-14 |
EP0920514B1 (en) | 2008-01-02 |
US6329190B1 (en) | 2001-12-11 |
WO1998007865A1 (en) | 1998-02-26 |
AU732770B2 (en) | 2001-04-26 |
US6649407B2 (en) | 2003-11-18 |
EP0920514A1 (en) | 1999-06-09 |
DE69738432T2 (de) | 2008-12-11 |
US20020151027A1 (en) | 2002-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001503250A (ja) | 束縛ペプチドモチーフを用いたターゲッティングアデノウイルス | |
US5712136A (en) | Adenoviral-mediated cell targeting commanded by the adenovirus penton base protein | |
CA2236912C (en) | Vectors and methods for gene transfer to cells | |
US6465253B1 (en) | Vectors and methods for gene transfer to cells | |
US6576456B2 (en) | Chimeric adenovirus fiber protein | |
US6455314B1 (en) | Alternatively targeted adenovirus | |
DE69637393T2 (de) | Vektoren und methoden zum gentransfer in zellen | |
ES2246533T3 (es) | Fibra adenovirica modificada y adenovirus dianas. | |
JP2000516098A (ja) | 短シャフトアデノウイルスファイバーおよびその用途 | |
AU2002344190B8 (en) | Adenovirus protein IX, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization | |
JP2003508057A (ja) | 改変アデノウイルスファイバーおよび用途 | |
JP2000157289A (ja) | 平滑筋細胞および/または内皮細胞への組織向性を与えられた遺伝子送達ベクタ― | |
JP2003514577A (ja) | 改変アデノウイルス繊維および使用 | |
MXPA98004203A (en) | Vectors and methods for gene transfer acelu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040723 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070919 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071018 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090217 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090608 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090721 |